Altimmune

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Altimmune and other ETFs, options, and stocks.

About ALT

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. 

CEO
Jerome B. Durso
CEOJerome B. Durso
Employees
59
Employees59
Headquarters
Gaithersburg, Maryland
HeadquartersGaithersburg, Maryland
Founded
1997
Founded1997
Employees
59
Employees59

ALT Key Statistics

Market cap
703.80M
Market cap703.80M
Price-Earnings ratio
-5.24
Price-Earnings ratio-5.24
Dividend yield
Dividend yield
Average volume
6.97M
Average volume6.97M
High today
$5.66
High today$5.66
Low today
$5.00
Low today$5.00
Open price
$5.05
Open price$5.05
Volume
6.28M
Volume6.28M
52 Week high
$7.73
52 Week high$7.73
52 Week low
$2.90
52 Week low$2.90

Stock Snapshot

As of today, Altimmune(ALT) shares are valued at $5.65. The company's market cap stands at 703.8M, with a P/E ratio of -5.24.

On 2026-02-02, Altimmune(ALT) stock moved within a range of $5.00 to $5.66. With shares now at $5.65, the stock is trading +13.0% above its intraday low and -0.1% below the session's peak.

Trading activity shows a volume of 6.28M, compared to an average daily volume of 6.97M.

The stock's 52-week range extends from a low of $2.90 to a high of $7.73.

The stock's 52-week range extends from a low of $2.90 to a high of $7.73.

ALT News

TipRanks 4d
Altimmune Announces $75 Million Registered Direct Equity Offering

Altimmune ( (ALT) ) has shared an announcement. On January 27, 2026, Altimmune, Inc. entered into a Securities Purchase Agreement with a new fundamental instit...

TipRanks 5d
Altimmune Raises $75M to Boost Obesity Drug Pipeline

Altimmune (ALT) has raised $75 million in new funding, giving the biotech company a boost as it continues developing its experimental obesity drug, pemvidutide....

TipRanks 5d
Altimmune prices $75M registered direct offering

Altimmune (ALT) “intends to use the net proceeds to fund preparation for its upcoming Phase 3 trial in metabolic dysfunction-associated steatohepatitis as well...

Analyst ratings

80%

of 10 ratings
Buy
80%
Hold
10%
Sell
10%

More ALT News

TipRanks 5d
Altimmune initiated with an Overweight at Barclays

Barclays initiated coverage of Altimmune (ALT) with an Overweight rating and $20 price target Barclays initiated coverage of 12 biotech stocks and assumed cover...

Simply Wall St 6d
Altimmune Valuation Check After Pemvidutide’s FDA Breakthrough Therapy Designation

Advertisement FDA Breakthrough designation puts pemvidutide in focus Altimmune (ALT) has drawn fresh attention after the FDA granted Breakthrough Therapy Desi...

Altimmune Valuation Check After Pemvidutide’s FDA Breakthrough Therapy Designation

People also own

Based on the portfolios of people who own ALT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.